tradingkey.logo
tradingkey.logo
Search

Aspire Biopharma Holdings Inc

ASBP
Add to Watchlist
6.680USD
-0.040-0.60%
Close 07-31 16:00ETQuotes delayed by 15 min
590.08KMarket Cap
LossP/E TTM

Aspire Biopharma Holdings Inc

6.680
-0.040-0.60%
View Detailed Chart
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-0.60%

5 Days

-7.99%

1 Month

+13.99%

6 Months

+213.62%

Year to Date

+26.61%

1 Year

+1652.82%

Key Figures
6.510Open
6.700High
9.53KVolume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
10.79%Turnover Ratio
6.720Prev. Close
6.360Low
51.68KTurnover
LossP/E Static
-0.09P/B
0.00%Div Yield TTM
-259.01%ROA
1050.36052wk High
0.23Volume Ratio
-12.54MNet Profit
88.34KShares
-6.9741EPS TTM
0.17Beta
-490.07%ROE
3.30952wk Low
5.06%Amplitude
20.28%Gross Margin
590.08KMarket Cap
0.73Reward/Risk
11.27%Risk Rate

Key Insights

Aspire Biopharma Holdings Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 202 out of 384 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Aspire Biopharma Holdings Inc's Score

Industry at a Glance

Industry Ranking
202 / 384
Overall Ranking
357 / 4280
Industry
Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Aspire Biopharma Holdings Inc Highlights

StrengthsRisks
Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.20K.
Undervalued
The company’s latest PE is -0.96, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 555.77K shares, increasing 39.35% quarter-over-quarter.

Analyst Rating

Based on 0 analysts
--
Current Rating
0.000
Target Price
0.00%
Upside Space

Aspire Biopharma Holdings Inc News

More news coming soon, stay tuned...

Indicators

Indicators
Sell(1)
Neutral(5)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
-0.132
Neutral
RSI(14)
51.043
Neutral
STOCH(KDJ)(9,3,3)
48.964
Neutral
ATR(14)
0.762
High Vlolatility
CCI(14)
-20.052
Neutral
Williams %R
50.000
Neutral
TRIX(12,20)
0.676
Sell
StochRSI(14)
47.501
Buy
Moving Average
Sell(1)
Neutral(0)
Buy(5)
Indicators
Value
Direction
MA5
6.613
Buy
MA10
6.942
Sell
MA20
6.466
Buy
MA50
6.106
Buy
MA100
4.019
Buy
MA200
2.832
Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Aspire Biopharma Holdings Inc Info

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Ticker SymbolASBP
CompanyAspire Biopharma Holdings Inc
CEO
Website

Shareholders

Shareholders
Shareholders
Proportion
Ardsley Advisory Partners LP
0.74%
Higginson (Kraig)
0.72%
UBS Financial Services, Inc.
0.53%
Friedman (Lance)
0.15%
Ajjarapu (Surendra K)
0.08%
Other
97.78%

FAQs

What is the current price of Aspire Biopharma Holdings Inc (ASBP)?

The current price of Aspire Biopharma Holdings Inc (ASBP) is 6.68.

What is the symbol of Aspire Biopharma Holdings Inc?

The ticker symbol of Aspire Biopharma Holdings Inc is ASBP.

What is the 52-week high of Aspire Biopharma Holdings Inc?

The 52-week high of Aspire Biopharma Holdings Inc is 1050.36.

What is the 52-week low of Aspire Biopharma Holdings Inc?

The 52-week low of Aspire Biopharma Holdings Inc is 3.31.

What is the market capitalization of Aspire Biopharma Holdings Inc?

The market capitalization of Aspire Biopharma Holdings Inc is 590.08K.

What is the Earnings Per Share (EPS TTM) of Aspire Biopharma Holdings Inc (ASBP)?

The Earnings Per Share (EPS TTM) of Aspire Biopharma Holdings Inc (ASBP) is -491.27.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.